Epidemiology and economics of statin use

Irish Medical Journal

Volumn 101, Issue 6, 2008, Pages

  Feely, J ^a   Bennett, K ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; HEALTH ECONOMICS; HEART DISEASE; HUMAN; UNITED KINGDOM; AGED; CORONARY ARTERY DISEASE; ECONOMICS; FEMALE; HYPERLIPIDEMIA; IRELAND; MALE; MIDDLE AGED; PHARMACOECONOMICS; PILOT STUDY;

AGED; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IRELAND; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 53449100214     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Irish Medical Journal 2006; 99:144-145.
2. Barry M, Heerey A. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland. Irish Medical Journal 2002; 95:133-135.
3. Kabir Z, Bennett K, Shelley E, Unal B, Critchley J, Feely J. The population mortality benefits of maximising the number of eligible patients receiving appropriate cardiology treatments in Ireland. Quarterly Journal of Medicine 2006; 99:523-530.
4. Byrne M, Murphy AW, Walsh IC, Shryane E, McGroarty M, Kelleher CC. A cross-sectional study of secondary cardiac care in general practice: impact of personal and practice characteristics. Family Practice 2006; 23:295-302.
5. Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients, Clinical Pharmacology and Therapeutics 2000, 67:438-441.
6. Walley T, Folino-Gallo P, Stephens & Van Ganse E, on behalf of the EuroMedStat Group. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. British Journal of Clinical Pharmacology 2005; 60:543-551.
7. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney IM, Miller E, Cain VA, Blasetto JW, for the STELLAR Study Group. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial). American Jounnal of Cardiology 2003; 92:152-160.
8. Bennett KE, Williams D, Feely L. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland. Irish Medical Journal 2002; 95:169-172.
9. Fourth Joint Task Force of the European Society of Cardiology., Graham I, Atar D, Borch-Johnsen K. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Executive Summary. European Heart Journal 2007; 28:2375-2414.
10. Barron TI, Bennett K, Feely J. Impact of high dose statin trials on hospital prescribers. European Journal of Clinical Pharmacology 2007; 63:65-72.